This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1991.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991
Title: The Innovative Mind of Yoshimasa Saitoh
Introduction: Yoshimasa Saitoh is a prominent inventor hailing from Osaka, Japan, renowned for his contributions to the field of biopharmaceuticals. With a focus on improving the stability and effectiveness of therapeutic proteins, Saitoh has made a significant impact in the pharmaceutical sector, particularly through his work at Fujisawa Pharmaceutical Company, Ltd.
Latest Patents: Saitoh holds a notable patent for IGF-I fusion proteins, which protect insulin-like growth factor 1 (IGF-I) from degradation by host mechanisms. This innovative approach involves fusing IGF-I with a protective peptide, ensuring its stability within E. coli cells. The patent also encompasses the genes coding for the fused IGF-I, plasmids containing these genes, and the transformed E. coli microorganisms. This invention has the potential to enhance the therapeutic applications of IGF-I by maintaining its integrity during production.
Career Highlights: Throughout his career, Yoshimasa Saitoh has demonstrated an unwavering commitment to advancing biopharmaceutical innovations. His work at Fujisawa Pharmaceutical Company, Ltd. has enabled him to lead cutting-edge research, contributing to the development of new drug formulations that improve patient outcomes.
Collaborations: Collaboration plays a vital role in Saitoh's success. He has worked closely with esteemed colleagues, such as Ikuo Ueda and Mineo Niwa, to advance their joint research initiatives. These partnerships have fostered a collaborative environment that drives innovation and expands the potential applications of their discoveries.
Conclusion: Yoshimasa Saitoh's inventive spirit and dedication to biopharmaceutical research highlight his importance in the field. Through his patent for IGF-I fusion proteins and collaborative efforts, Saitoh continues to pave the way for advancements that can significantly impact healthcare and therapeutic development. His contributions are noteworthy, demonstrating how innovation in biopharmaceuticals can lead to enhanced treatment options for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile